Literature DB >> 29680012

Salvage radiotherapy after radical prostatectomy: Preserving patient quality of life with modern treatment techniques.

Martin Korzeniowski1.   

Abstract

Entities:  

Year:  2017        PMID： 29680012      PMCID： PMC5937411          DOI： 10.5489/cuaj.5112

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  5 in total

1.  Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

Authors:  Jeff M Michalski; Yan Yan; Deborah Watkins-Bruner; Walter R Bosch; Kathryn Winter; James M Galvin; Jean-Paul Bahary; Gerard C Morton; Matthew B Parliament; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-08       Impact factor: 7.038

2.  Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.

Authors:  Rahul D Tendulkar; Shree Agrawal; Tianming Gao; Jason A Efstathiou; Thomas M Pisansky; Jeff M Michalski; Bridget F Koontz; Daniel A Hamstra; Felix Y Feng; Stanley L Liauw; Matthew C Abramowitz; Alan Pollack; Mitchell S Anscher; Drew Moghanaki; Robert B Den; Kevin L Stephans; Anthony L Zietman; W Robert Lee; Michael W Kattan; Andrew J Stephenson
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

3.  Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy.

Authors:  Maria Pearse; Richard Choo; Cyril Danjoux; Sandra Gardner; Gerard Morton; Ewa Szumacher; Andrew Loblaw; Patrick Cheung
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-15       Impact factor: 7.038

4.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

5.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.